Pharmaceuticals

At BIO 2026, Israeli biotech Can-Fite seeks crucial partnerships for its late-stage cancer and inflammation drugs, built on a unique, safety-focused platform.

Choosing the wrong regulatory partner can derail a market launch. A new guide from Q&C Services offers a veteran's roadmap for de-risking expansion.

Azitra is betting its future on a radical pivot, leveraging its science for cosmetics and biotech tools. Is this a savvy move for faster cash or a risky dilution of focus?

A new survey reveals the deep toll of canine skin allergies on pets and owners, exposing a massive unmet need that has pharmaceutical giants racing for a cure.

ARMR Sciences reports a major breakthrough in the fight against overdose, but can a preventative vaccine truly turn the tide on the fentanyl crisis?

A new collaboration aims to weaponize the immune system against tough GI cancers. We break down the science, strategy, and nearly $800M per program deal.

A Swedish pharma company's trial is progressing faster than expected, but the real story is the potential paradigm shift for millions suffering from a neglected disease.

A new AU$481M deal with Everest Medicines brings a promising FSGS drug closer to 1M Asian patients, part of a larger, de-risked global strategy.

With 33% growth dwarfing industry norms, NNB Nutrition's integrated model and fermentation tech aren't just winning—they're rewriting the rules for wellness.

Assertio Holdings delists from Nasdaq after its merger with Zydus. A deep dive into the strategic calculus and the crucial decision facing its debt holders.

Biotech firm Azitra is leveraging its engineered microbe tech to tackle rare diseases and enter the $71B cosmeceutical market. Is this a brilliant pivot or a risky bet?

New appointments bring deep legal and pharma expertise to Canada's Patented Medicine Prices Review Board, signaling a pivotal moment under new 2026 guidelines.

A new bill named for a man failed by the system aims to modernize medical psilocybin access. But can it overcome bureaucratic inertia and position Canada as a leader?

As a rare Ebola strain rages in a DRC warzone, the G7 pledges massive aid. But with fragile peace deals and no proven cure, is it enough to stop a global crisis?

Medincell's latest results show a planned loss but reveal a strategic shift to recurring royalties, fueled by UZEDY®'s success and a pipeline set for growth.

A forgotten corner of oncology is set for a 14.2% CAGR. A new wave of drugs for chemo-induced neuropathy signals a major market realignment.

Nomic and the Wellcome Sanger Institute unite to profile immune diversity in underrepresented populations, using proteomics to bridge the gap from gene to function.

As nations race to finalize a pandemic treaty, a battle over enforceable equity threatens to derail the entire process. Will it be a new era of cooperation or a repeat of past failures?

The inaugural Young American Scientists list spotlights brilliant minds. But behind the accolades lies a system in crisis, threatening America's innovation.

A new partnership aims to disrupt the opaque PBM industry. By pairing a transparent model with modern tech, it could finally lower your prescription costs.